Chronic viral coinfections differentially affect the likelihood of developing long COVID
BACKGROUNDThe presence and reactivation of chronic viral infections, such as EBV, CMV, and HIV, have been proposed as potential contributors to long COVID (LC), but studies in well-characterized postacute cohorts of individuals with COVID-19 over a longer time course consistent with current case definitions of LC are limited.METHODSIn a cohort of 280 adults with prior SARS-CoV-2 infection, we assessed the presence and types of LC symptoms and prior medical history (including COVID-19 history and HIV status) and performed serological testing for EBV and CMV using a commercial laboratory. We used covariate-adjusted binary logistic regression models to identify independent associations between variables and LC symptoms.RESULTSWe observed that LC symptoms, such as fatigue and neurocognitive dysfunction, at a median of 4 months following initial diagnosis were independently associated with serological evidence suggesting recent EBV reactivation (early antigen-diffuse IgG positivity) or high nuclear antigen (EBNA) IgG levels but not with ongoing EBV viremia. Serological evidence suggesting recent EBV reactivation (early antigen-diffuse IgG positivity) was most strongly associated with fatigue (OR = 2.12). Underlying HIV infection was also independently associated with neurocognitive LC (OR = 2.5). Interestingly, participants who had serologic evidence of prior CMV infection were less likely to develop neurocognitive LC (OR = 0.52).CONCLUSIONOverall, these findings suggest differential effects of chronic viral coinfections on the likelihood of developing LC and association with distinct syndromic patterns. Further assessment during the acute phase of COVID-19 is warranted.TRIAL REGISTRATIONLong-term Impact of Infection with Novel Coronavirus; ClinicalTrials.gov NCT04362150.FUNDINGThis work was supported by NIH/National Institute of Allergy and Infectious Diseases grants (3R01AI141003-03S1, R01AI158013, and K24AI145806); the Zuckerberg San Francisco General Hospital Department of Medicine and Division of HIV, Infectious Diseases, and Global Medicine; and the UCSF-Bay Area Center for AIDS Research (P30-AI027763).
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:133 |
|---|---|
| Enthalten in: |
The Journal of clinical investigation - 133(2023), 3 vom: 01. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Peluso, Michael J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adaptive immunity |
|---|
| Anmerkungen: |
Date Completed 02.02.2023 Date Revised 06.11.2023 published: Electronic ClinicalTrials.gov: NCT04362150 UpdateOf: medRxiv. 2022 Jul 22;:. - PMID 35898346 Citation Status MEDLINE |
|---|
| doi: |
10.1172/JCI163669 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349672733 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349672733 | ||
| 003 | DE-627 | ||
| 005 | 20231226043203.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1172/JCI163669 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1165.xml |
| 035 | |a (DE-627)NLM349672733 | ||
| 035 | |a (NLM)36454631 | ||
| 035 | |a (PII)e163669 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Peluso, Michael J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chronic viral coinfections differentially affect the likelihood of developing long COVID |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.02.2023 | ||
| 500 | |a Date Revised 06.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04362150 | ||
| 500 | |a UpdateOf: medRxiv. 2022 Jul 22;:. - PMID 35898346 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUNDThe presence and reactivation of chronic viral infections, such as EBV, CMV, and HIV, have been proposed as potential contributors to long COVID (LC), but studies in well-characterized postacute cohorts of individuals with COVID-19 over a longer time course consistent with current case definitions of LC are limited.METHODSIn a cohort of 280 adults with prior SARS-CoV-2 infection, we assessed the presence and types of LC symptoms and prior medical history (including COVID-19 history and HIV status) and performed serological testing for EBV and CMV using a commercial laboratory. We used covariate-adjusted binary logistic regression models to identify independent associations between variables and LC symptoms.RESULTSWe observed that LC symptoms, such as fatigue and neurocognitive dysfunction, at a median of 4 months following initial diagnosis were independently associated with serological evidence suggesting recent EBV reactivation (early antigen-diffuse IgG positivity) or high nuclear antigen (EBNA) IgG levels but not with ongoing EBV viremia. Serological evidence suggesting recent EBV reactivation (early antigen-diffuse IgG positivity) was most strongly associated with fatigue (OR = 2.12). Underlying HIV infection was also independently associated with neurocognitive LC (OR = 2.5). Interestingly, participants who had serologic evidence of prior CMV infection were less likely to develop neurocognitive LC (OR = 0.52).CONCLUSIONOverall, these findings suggest differential effects of chronic viral coinfections on the likelihood of developing LC and association with distinct syndromic patterns. Further assessment during the acute phase of COVID-19 is warranted.TRIAL REGISTRATIONLong-term Impact of Infection with Novel Coronavirus; ClinicalTrials.gov NCT04362150.FUNDINGThis work was supported by NIH/National Institute of Allergy and Infectious Diseases grants (3R01AI141003-03S1, R01AI158013, and K24AI145806); the Zuckerberg San Francisco General Hospital Department of Medicine and Division of HIV, Infectious Diseases, and Global Medicine; and the UCSF-Bay Area Center for AIDS Research (P30-AI027763) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Adaptive immunity | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Cytokines | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Deveau, Tyler-Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Munter, Sadie E |e verfasserin |4 aut | |
| 700 | 1 | |a Ryder, Dylan |e verfasserin |4 aut | |
| 700 | 1 | |a Buck, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Beck-Engeser, Gabriele |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Fay |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Scott |e verfasserin |4 aut | |
| 700 | 1 | |a Goldberg, Sarah A |e verfasserin |4 aut | |
| 700 | 1 | |a Hoh, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Tai, Viva |e verfasserin |4 aut | |
| 700 | 1 | |a Torres, Leonel |e verfasserin |4 aut | |
| 700 | 1 | |a Iyer, Nikita S |e verfasserin |4 aut | |
| 700 | 1 | |a Deswal, Monika |e verfasserin |4 aut | |
| 700 | 1 | |a Ngo, Lynn H |e verfasserin |4 aut | |
| 700 | 1 | |a Buitrago, Melissa |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jessica Y |e verfasserin |4 aut | |
| 700 | 1 | |a Yee, Brandon C |e verfasserin |4 aut | |
| 700 | 1 | |a Chenna, Ahmed |e verfasserin |4 aut | |
| 700 | 1 | |a Winslow, John W |e verfasserin |4 aut | |
| 700 | 1 | |a Petropoulos, Christos J |e verfasserin |4 aut | |
| 700 | 1 | |a Deitchman, Amelia N |e verfasserin |4 aut | |
| 700 | 1 | |a Hellmuth, Joanna |e verfasserin |4 aut | |
| 700 | 1 | |a Spinelli, Matthew A |e verfasserin |4 aut | |
| 700 | 1 | |a Durstenfeld, Matthew S |e verfasserin |4 aut | |
| 700 | 1 | |a Hsue, Priscilla Y |e verfasserin |4 aut | |
| 700 | 1 | |a Kelly, J Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, Jeffrey N |e verfasserin |4 aut | |
| 700 | 1 | |a Deeks, Steven G |e verfasserin |4 aut | |
| 700 | 1 | |a Hunt, Peter W |e verfasserin |4 aut | |
| 700 | 1 | |a Henrich, Timothy J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of clinical investigation |d 1924 |g 133(2023), 3 vom: 01. Feb. |w (DE-627)NLM000005487 |x 1558-8238 |7 nnns |
| 773 | 1 | 8 | |g volume:133 |g year:2023 |g number:3 |g day:01 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1172/JCI163669 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 133 |j 2023 |e 3 |b 01 |c 02 | ||